Skip to content

Fitbit Assessed PS in Colorectal Cancer

Get Your Rear In Gear Study: Feasibility of Using Fitness Tracker to Assess Activity Level and Toxicities in Patients With Localized/Advanced Colorectal Cancer: A Fox Chase Cancer Center Pilot Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07084181
Enrollment
80
Registered
2025-07-24
Start date
2017-02-15
Completion date
2019-07-22
Last updated
2025-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer (Diagnosis)

Keywords

Colorectal Cancer, Patient Reported Outcomes, Fitness Tracker

Brief summary

Primary Objective To assess the feasibility of activity tracking using Fitbit device in terms of compliance (defined as at least 75% of patients complying with instructions to wear the device, for at least 12 hours a day on at least 3 of the 4 assigned days) in patients undergoing therapy for localized and advanced colorectal cancer. Secondary Objectives * To determine if physician-assessed performance status correlates with FitbitTM assessed physical activity (using active-minutes data). * To correlate baseline physical activity level as assessed by FitbitTM with incidence of grade III or higher toxicities experienced during treatment * To assess correlation between patient reported treatment related toxicities (PRO-CTCAE) and objective physical activity as measured by FitbitTM in patients treated for localized or metastatic cancers treated with chemotherapy * To correlate baseline and interval change in physical activity levels as assessed by FitbitTM with post-surgical outcomes including inpatient length of stay, perioperative complications, post-operative 30-day mortality, and time to adjuvant treatment initiation (in days)

Interventions

None listed

Sponsors

Fox Chase Cancer Center
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 18 years or older * Have histologically confirmed colorectal adenocarcinoma (Stage II-IV) * Have an estimated life expectancy of greater than 3 months * Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 * Should meet the following treatment arms: * Planned to undergo curative resection with or without neoadjuvant/adjuvant therapy for colorectal cancer (surgical arm); * Planned to undergo/undergoing systemic chemotherapy for localized/metastatic colorectal cancer - medical arm (patient enrolled on one arm may not enroll onto the other arm) * Able to participate in some degree of physical activity (i.e. walking) * Are undergoing treatment for their cancer at FCCC * Ability to understand and willingness to sign a written informed consent and HIPAA consent

Exclusion criteria

* Inability to communicate in English. * Already using a personal activity tracker * Enrolled in another study in which physical activity is part or all of the therapeutic intervention or is being evaluated * Pre-existing toxicity \>grade II * PS \>3 for any reason

Design outcomes

Primary

MeasureTime frameDescription
Rate of usage4 daysTo assess the feasibility of activity tracking using Fitbit device in terms of compliance (defined as at least 75% of patients complying with instructions to wear the device, for at least 12 hours a day on at least 3 of the 4 assigned days) in patients undergoing therapy for localized and advanced colorectal cancer.
Stepsenrollment to 7 daystracker assessed step count

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026